AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 19204509 — intervention group
Group type: COMPARATOR
Intervention: RBC (up to 9 units)
Number of subjects: 688
Study 19204509 — intervention group
Group type: EXPERIMENTAL
Intervention: HBOC-201
Number of subjects: 688
Study 19204509 — intervention group
Group type: COMPARATOR
Intervention: RBC
Number of subjects: 688
Study 17302656 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated care
Number of subjects: 524
Study 17302656 — intervention group
Group type: COMPARATOR
Intervention: Enhanced specialty referral care
Number of subjects: 524
Study 15059636 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E 400 IU daily for 6 months
Number of subjects: 110
Study 15059636 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 110
Study 11588286 — intervention group
Group type: EXPERIMENTAL
Intervention: Video role play with structured feedback
Number of subjects: 132
Study 11588286 — intervention group
Group type: COMPARATOR
Intervention: Control group (no training intervention)
Number of subjects: 132
Study 10189388 — intervention group
Group type: EXPERIMENTAL
Intervention: Teicoplanin
Number of subjects: 66
Study 10189388 — intervention group
Group type: EXPERIMENTAL
Intervention: Vancomycin
Number of subjects: 66
Study 7538815 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human interleukin-6 (rhIL-6) at 1.0, 2.5, 3.75, and 5.0 micrograms/kg/d
Number of subjects: 22
Study 7538815 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human interleukin-6 (rhIL-6) at 5.0 micrograms/kg/d
Number of subjects: 22
Study 7538815 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human interleukin-6 (rhIL-6) at 3.75 micrograms/kg/d
Number of subjects: 22
Study 7538815 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human interleukin-6 (rhIL-6) maintenance therapy
Number of subjects: 22
Study 7538815 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human interleukin-6 (rhIL-6)
Number of subjects: 22
Study 2177394 — intervention group
Group type: EXPERIMENTAL
Intervention: Carboplatin (CP) 167‐436 mg/m2 by intravenous infusion, repeated every 4 weeks, 2‐4 cycles
Number of subjects: 243
Study 2177394 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination chemotherapy containing CP (CE: CP + VP ‐ 16)
Number of subjects: 243
Study 2177394 — intervention group
Group type: COMPARATOR
Intervention: Combination chemotherapy containing DDP (PE: DDP + VP ‐ 16)
Number of subjects: 243
Study 2177394 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination chemotherapy containing CP (CAC: CP + adriamycin + cyclophosphamide)
Number of subjects: 243
Study 2177394 — intervention group
Group type: COMPARATOR
Intervention: Combination chemotherapy containing DDP (PAC: DDP + adriamycin + cyclophosphamide)
Number of subjects: 243
Study 7406654 — intervention group
Group type: EXPERIMENTAL
Intervention: Methadyl acetate administered on Friday, starting dose identical to previously established methadone dose, flexible thereafter.
Number of subjects: 136
Study 7406654 — intervention group
Group type: COMPARATOR
Intervention: Daily methadone comparison group.
Number of subjects: 136
Study 30229398 — intervention group
Group type: EXPERIMENTAL
Intervention: Enteric-coated mycophenolate sodium (EC-MPS) administered to elderly renal transplant recipients
Number of subjects: 44
Study 27831462 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical exercise program (20 sessions of strengthening, balance, and walking over 4 weeks)
Number of subjects: 160
Study 27831462 — intervention group
Group type: COMPARATOR
Intervention: Social interaction sessions (equivalent duration and frequency to EG, without physical exercise)
Number of subjects: 160
Study 27831462 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical exercise program
Number of subjects: 160
Study 27831462 — intervention group
Group type: COMPARATOR
Intervention: Social interaction sessions
Number of subjects: 160
Study 25850024 — intervention group
Group type: EXPERIMENTAL
Intervention: Hybrid-variable priority training (HVT) program for 8 weeks
Number of subjects: 28
Study 25850024 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control group
Number of subjects: 28
Study 24124930 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritional and eating education for 6 months
Number of subjects: 162
Study 21070781 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide 9 mg/day (once daily)
Number of subjects: 309
Study 21070781 — intervention group
Group type: COMPARATOR
Intervention: Mesalamine 4.5 g/day
Number of subjects: 309
Study 21070781 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide 3 mg/day (3 times daily)
Number of subjects: 309
Study 21070781 — intervention group
Group type: COMPARATOR
Intervention: Budesonide vs Mesalamine
Number of subjects: 309
Study 19092729 — intervention group
Group type: EXPERIMENTAL
Intervention: Valdecoxib and parecoxib (40 mg IV every 6 hours on day one postoperative)
Number of subjects: 116
Study 19092729 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 116
Study 19092729 — intervention group
Group type: EXPERIMENTAL
Intervention: Valdecoxib
Number of subjects: 116
Study 17712135 — intervention group
Group type: EXPERIMENTAL
Intervention: Overweight children
Number of subjects: 1069
Study 17712135 — intervention group
Group type: EXPERIMENTAL
Intervention: Obese children
Number of subjects: 1069
Study 15448515 — intervention group
Group type: EXPERIMENTAL
Intervention: Video-assisted fiberoptic intubation
Number of subjects: 20
Study 15448515 — intervention group
Group type: COMPARATOR
Intervention: Traditional fiberoptic intubation
Number of subjects: 20
Study 11426006 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-body MR imaging with real-time true fast imaging with steady-state precession
Number of subjects: 5
Study 11426006 — intervention group
Group type: COMPARATOR
Intervention: Thoracic and abdominal helical computed tomography
Number of subjects: 5
Study 11218929 — intervention group
Group type: EXPERIMENTAL
Intervention: Waterless hand preparation (HP) containing 61% ethyl alcohol, 1% CHG, and emollients
Number of subjects: 20
Study 11218929 — intervention group
Group type: COMPARATOR
Intervention: Traditional surgical scrub (TSS)
Number of subjects: 20
Study 9232709 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin therapy in health care centre
Number of subjects: 28
Study 9232709 — intervention group
Group type: COMPARATOR
Intervention: Insulin therapy in day-care clinic
Number of subjects: 28
Study 8358075 — intervention group
Group type: EXPERIMENTAL
Intervention: New flavoured PEG solution for gut lavage
Number of subjects: 160
Study 8358075 — intervention group
Group type: COMPARATOR
Intervention: Standard preparation (2‐day semi‐liquid diet, laxatives and cleansing enemas)
Number of subjects: 160
Study 3313678 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-aminosalicylic acid (5-ASA) 1500 mg slow-release/day (Pentasa)
Number of subjects: 67
Study 3313678 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 67
Study 3313678 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-aminosalicylic acid (5-ASA)
Number of subjects: 67
Study 2175687 — intervention group
Group type: EXPERIMENTAL
Intervention: Lipiodol Ultra Fluid
Number of subjects: 60
Study 2175687 — intervention group
Group type: COMPARATOR
Intervention: Urografin 290
Number of subjects: 60
Study 1062910 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg of ferrous iron daily
Number of subjects: 50
Study 1062910 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 31094798 — intervention group
Group type: EXPERIMENTAL
Intervention: Glidescope + fiberscope
Number of subjects: 160
Study 31094798 — intervention group
Group type: COMPARATOR
Intervention: Standard Glidescope
Number of subjects: 160
Study 27376411 — intervention group
Group type: EXPERIMENTAL
Intervention: eCBT (exposure-based cognitive behavioural therapy)
Number of subjects: 181
Study 27376411 — intervention group
Group type: COMPARATOR
Intervention: Genetic variants
Number of subjects: 181
Study 27376411 — intervention group
Group type: COMPARATOR
Intervention: Gene expression
Number of subjects: 181
Study 25238699 — intervention group
Group type: COMPARATOR
Intervention: Mineral oil (control group; n = 17)
Number of subjects: 50
Study 25238699 — intervention group
Group type: EXPERIMENTAL
Intervention: Olive oil (n = 16)
Number of subjects: 50
Study 25238699 — intervention group
Group type: EXPERIMENTAL
Intervention: Flaxseed oil (n = 17)
Number of subjects: 50
Study 24939817 — intervention group
Group type: EXPERIMENTAL
Intervention: 24h pretreatment with dexamethasone (0.5 mg/kg/dose, q6h, total of six doses; n = 66)
Number of subjects: 124
Study 24939817 — intervention group
Group type: COMPARATOR
Intervention: 6h pretreatment with dexamethasone (total of three doses; n = 58)
Number of subjects: 124
Study 24939817 — intervention group
Group type: EXPERIMENTAL
Intervention: 24h pretreatment with dexamethasone
Number of subjects: 124
Study 24939817 — intervention group
Group type: COMPARATOR
Intervention: 6h pretreatment with dexamethasone
Number of subjects: 124
Study 22214352 — intervention group
Group type: EXPERIMENTAL
Intervention: Active inspiratory exercise programme for eight months
Number of subjects: 26
Study 22214352 — intervention group
Group type: COMPARATOR
Intervention: Placebo exercise programme for the first four months followed by active exercise for the second four-month period
Number of subjects: 26
Study 22214352 — intervention group
Group type: EXPERIMENTAL
Intervention: Inspiratory exercise
Number of subjects: 26
Study 19776028 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol/paravertebral anaesthesia‐analgesia
Number of subjects: 22
Study 19776028 — intervention group
Group type: COMPARATOR
Intervention: Sevoflurane general anaesthesia with opioid analgesia
Number of subjects: 22
Study 19776028 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 22
Study 17264136 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive geriatric assessment and management consultations
Number of subjects: 345
Study 17264136 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 345
Study 17264136 — intervention group
Group type: COMPARATOR
Intervention: External comparison group (no GEM teams)
Number of subjects: 345
Study 15140531 — intervention group
Group type: EXPERIMENTAL
Intervention: Early initiation of Tirofiban
Number of subjects: 507
Study 15140531 — intervention group
Group type: COMPARATOR
Intervention: Late initiation of Tirofiban
Number of subjects: 507
Study 12460127 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual-guided outpatient treatments
Number of subjects: 600
Study 12460127 — intervention group
Group type: COMPARATOR
Intervention: No specific intervention mentioned
Number of subjects: 600
Study 9806127 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenoxicam (20 mg daily, n = 23)
Number of subjects: 48
Study 9806127 — intervention group
Group type: COMPARATOR
Intervention: L-EE (1 tablet containing 0.05 mg + 2.5 mg, 3 times daily, n = 25)
Number of subjects: 48
Study 7617153 — intervention group
Group type: EXPERIMENTAL
Intervention: Right visual field for categorical judgements
Number of subjects: 104
Study 7617153 — intervention group
Group type: EXPERIMENTAL
Intervention: Left visual field for coordinate judgements
Number of subjects: 104
Study 7617153 — intervention group
Group type: EXPERIMENTAL
Intervention: Right-handed subjects
Number of subjects: 104
Study 7617153 — intervention group
Group type: COMPARATOR
Intervention: Left-handed subjects
Number of subjects: 104
Study 2536211 — intervention group
Group type: EXPERIMENTAL
Intervention: Extruded meal (40 g) with milk, 58Fe (1.253 mg) and 67Zn (5.13 mg) administered
Number of subjects: 0
Study 2536211 — intervention group
Group type: COMPARATOR
Intervention: Nonextruded meal (40 g) with milk, 58Fe (1.253 mg) and 67Zn (5.13 mg) administered
Number of subjects: 0
Study 344107 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-fluorouracil (5FU)
Number of subjects: 159
Study 344107 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-fluorouracil (5FU) and BCG
Number of subjects: 159
Study 31987796 — intervention group
Group type: EXPERIMENTAL
Intervention: Synbiotic agents (fructo-oligosaccharides, 4 g twice per day, plus Bifidobacterium animalis subspecies lactis BB-12; n=55)
Number of subjects: 104
Study 31987796 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n=49)
Number of subjects: 104
Study 30772827 — intervention group
Group type: EXPERIMENTAL
Intervention: E‐cigarette advertisement with a fake warning
Number of subjects: 775
Study 30772827 — intervention group
Group type: COMPARATOR
Intervention: Other e‐cigarette advertisements (control)
Number of subjects: 775
Study 28099236 — intervention group
Group type: EXPERIMENTAL
Intervention: Perfluorohexane treatment (endotracheal instillation) in addition to conventional treatment.
Number of subjects: 23
Study 28099236 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment (anti-infection, nutritional support, antishock measures, and supportive treatment).
Number of subjects: 23
Study 25847401 — intervention group
Group type: EXPERIMENTAL
Intervention: BCAA supplementation (two times a day added to a conventional diet)
Number of subjects: 28
Study 23521170 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical ketamine (0.4 ml, 20 mg)
Number of subjects: 60
Study 23521170 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical tramadol (0.8 ml)
Number of subjects: 60
Study 23521170 — intervention group
Group type: COMPARATOR
Intervention: Control group (5 ml saline)
Number of subjects: 60
Study 22039471 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab 500 mg/m², given twice two weeks apart
Number of subjects: 30
Study 22039471 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 30
Study 22039471 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab
Number of subjects: 30
Study 19040308 — intervention group
Group type: EXPERIMENTAL
Intervention: Methotrexate (MTX)
Number of subjects: 71
Study 19040308 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 71
Study 17524529 — intervention group
Group type: EXPERIMENTAL
Intervention: Meningococcal polysaccharide vaccines
Number of subjects: 0
Study 17524529 — intervention group
Group type: COMPARATOR
Intervention: Fixed four-fold increase in rSBA
Number of subjects: 0
Study 15631963 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet questionnaire (n=221)
Number of subjects: 442
Study 15631963 — intervention group
Group type: COMPARATOR
Intervention: Mailed questionnaire (n=221)
Number of subjects: 442
Study 11712036 — intervention group
Group type: EXPERIMENTAL
Intervention: Commercial zinc pyrithione (ZPT) shampoo
Number of subjects: 0
Study 11712036 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 9642594 — intervention group
Group type: EXPERIMENTAL
Intervention: MicroVisc Plus
Number of subjects: 100
Study 9642594 — intervention group
Group type: COMPARATOR
Intervention: Healon GV
Number of subjects: 100
Study 9642594 — intervention group
Group type: EXPERIMENTAL
Intervention: Healon GV/MicroVisc Plus
Number of subjects: 100
Study 9642594 — intervention group
Group type: COMPARATOR
Intervention: Healon/MicroVisc
Number of subjects: 100
Study 7808206 — intervention group
Group type: EXPERIMENTAL
Intervention: Rating scale
Number of subjects: 40
Study 7808206 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard gamble
Number of subjects: 40
Study 2783697 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine
Number of subjects: 28
Study 2783697 — intervention group
Group type: COMPARATOR
Intervention: Amitryptiline
Number of subjects: 28
Study 1097220 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate
Number of subjects: 0
Study 31577792 — intervention group
Group type: EXPERIMENTAL
Intervention: Text messaging intervention (up to 14 text messages during pregnancy and after delivery)
Number of subjects: 2515
Study 31577792 — intervention group
Group type: COMPARATOR
Intervention: Control group (no text messaging intervention)
Number of subjects: 2515
Study 30072745 — intervention group
Group type: EXPERIMENTAL
Intervention: S-1 plus cisplatin
Number of subjects: 375
Study 30072745 — intervention group
Group type: COMPARATOR
Intervention: Cisplatin alone
Number of subjects: 375
Study 24828795 — intervention group
Group type: EXPERIMENTAL
Intervention: Personal Respiratory Sampling Test (PRST)
Number of subjects: 84
Study 24828795 — intervention group
Group type: COMPARATOR
Intervention: Conventional Portacount fit‐test method
Number of subjects: 84
Study 23836508 — intervention group
Group type: EXPERIMENTAL
Intervention: Video messages from a media campaign
Number of subjects: 1677
Study 23836508 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 1677
Study 22770436 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity disease management (HDM)
Number of subjects: 0
Study 22770436 — intervention group
Group type: COMPARATOR
Intervention: Not specified
Number of subjects: 0
Study 19554196 — intervention group
Group type: EXPERIMENTAL
Intervention: Respimat Soft Mist Inhaler (SMI) (200 or 400 microg bd)
Number of subjects: 153
Study 19554196 — intervention group
Group type: COMPARATOR
Intervention: Turbuhaler dry powder inhaler (400 microg bd)
Number of subjects: 153
Study 17549293 — intervention group
Group type: EXPERIMENTAL
Intervention: AHF (High Purity)
Number of subjects: 12
Study 17549293 — intervention group
Group type: EXPERIMENTAL
Intervention: Biostate
Number of subjects: 12
Study 17549293 — intervention group
Group type: EXPERIMENTAL
Intervention: Both AHF (High Purity) and Biostate
Number of subjects: 12
Study 17549293 — intervention group
Group type: EXPERIMENTAL
Intervention: AHF (High Purity) and Biostate
Number of subjects: 12
Study 15179342 — intervention group
Group type: EXPERIMENTAL
Intervention: Diluted cardioplegia (4:1 blood to crystalloid ratio; n=25)
Number of subjects: 59
Study 15179342 — intervention group
Group type: COMPARATOR
Intervention: Minicardioplegia (undiluted; n=34)
Number of subjects: 59
Study 12243915 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen 20 mg/day for 5 years
Number of subjects: 7152
Study 12243915 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7152
Study 12243915 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen
Number of subjects: 7152
Study 9519420 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium oxalate crystalluria in stone formers (n=11)
Number of subjects: 22
Study 9519420 — intervention group
Group type: COMPARATOR
Intervention: Calcium oxalate crystalluria in control subjects (n=11)
Number of subjects: 22
Study 9519420 — intervention group
Group type: EXPERIMENTAL
Intervention: Crystalluric subjects (n=7)
Number of subjects: 22
Study 7827647 — intervention group
Group type: EXPERIMENTAL
Intervention: Anakinra
Number of subjects: 0
Study 2817624 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxygen (O2)
Number of subjects: 9
Study 2817624 — intervention group
Group type: COMPARATOR
Intervention: Compressed air
Number of subjects: 9
Study 1119396 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.25 mg digoxin daily
Number of subjects: 21
Study 1119396 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg digoxin daily
Number of subjects: 21
Study 1119396 — intervention group
Group type: COMPARATOR
Intervention: Control patients (no digoxin)
Number of subjects: 21
Study 1119396 — intervention group
Group type: EXPERIMENTAL
Intervention: Variable doses of digoxin (0 to 0.75 mg)
Number of subjects: 21
Study 30361077 — intervention group
Group type: EXPERIMENTAL
Intervention: Proprioceptive neuromuscular facilitation training
Number of subjects: 44
Study 30361077 — intervention group
Group type: COMPARATOR
Intervention: General trunk exercises
Number of subjects: 44
Study 27256575 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-intervention assessment completion
Number of subjects: 0
Study 27256575 — intervention group
Group type: COMPARATOR
Intervention: Overall participation
Number of subjects: 0
Study 27256575 — intervention group
Group type: EXPERIMENTAL
Intervention: Reach and representativeness
Number of subjects: 0
Study 25637007 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical coconut oil applications
Number of subjects: 258
Study 25637007 — intervention group
Group type: COMPARATOR
Intervention: Control group (no coconut oil applications)
Number of subjects: 258
Study 23941633 — intervention group
Group type: EXPERIMENTAL
Intervention: Goal management intervention (psycho-educational program with six group meetings and homework assignments)
Number of subjects: 0
Study 23941633 — intervention group
Group type: EXPERIMENTAL
Intervention: Goal management intervention
Number of subjects: 0
Study 23941633 — intervention group
Group type: COMPARATOR
Intervention: Waiting list control condition
Number of subjects: 0
Study 21397384 — intervention group
Group type: EXPERIMENTAL
Intervention: New course design (interventional group)
Number of subjects: 66
Study 21397384 — intervention group
Group type: COMPARATOR
Intervention: Standard course design (control group)
Number of subjects: 66
Study 18596389 — intervention group
Group type: EXPERIMENTAL
Intervention: Sorafenib as a single-agent therapy
Number of subjects: 0
Study 18596389 — intervention group
Group type: COMPARATOR
Intervention: Sorafenib in combination with carboplatin and paclitaxel
Number of subjects: 0
Study 18596389 — intervention group
Group type: EXPERIMENTAL
Intervention: Dacarbazine (DTIC) plus sorafenib
Number of subjects: 0
Study 18596389 — intervention group
Group type: EXPERIMENTAL
Intervention: Temozolomide plus sorafenib
Number of subjects: 0
Study 16671363 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual Reality (VR) immersion
Number of subjects: 20
Study 16671363 — intervention group
Group type: COMPARATOR
Intervention: Control (no VR exposure)
Number of subjects: 20
Study 12954304 — intervention group
Group type: EXPERIMENTAL
Intervention: Silicone CeeOn Edge IOL
Number of subjects: 78
Study 12954304 — intervention group
Group type: COMPARATOR
Intervention: Acrylate AcrySof IOL
Number of subjects: 78
Study 11095456 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly GH dose (natural log transformation)
Number of subjects: 843
Study 11095456 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxandrolone treatment
Number of subjects: 843
Study 11095456 — intervention group
Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 843
Study 11095456 — intervention group
Group type: EXPERIMENTAL
Intervention: Distance between height and target height (SD score)
Number of subjects: 843
Study 11095456 — intervention group
Group type: EXPERIMENTAL
Intervention: Body weight SD
Number of subjects: 843
Study 11095456 — intervention group
Group type: EXPERIMENTAL
Intervention: Number of GH injections per week
Number of subjects: 843
Study 11095456 — intervention group
Group type: EXPERIMENTAL
Intervention: Karyotype
Number of subjects: 843